卡瑞利珠单抗联合化疗在Ⅲ期NSCLC患者术前新辅助治疗中的应用效果  

Effect of Carrilizumab Combined with Chemotherapy on Preoperative Neoadjuvant Therapy in Patients with Stage Ⅲ NSCLC

作　　者：汤少鹏[1] 周晓蕾[1] 陈家令[1] TANG Shaopeng;ZHOU Xiaolei;CHEN Jialing(Henan Chest Hospital,Zhengzhou,450003)

机构地区：[1]河南省胸科医院,450003

出　　处：《实用癌症杂志》2025年第2期214-217,共4页The Practical Journal of Cancer

基　　金：河南省医学联合共建项目(编号:LHGJ20210230)。

摘　　要：目的 分析卡瑞利珠单抗联合化疗在Ⅲ期非小细胞肺癌(NSCLC)患者术前新辅助治疗中的应用效果。方法 挑选NSCLCⅢ期患者共82例,随机分成2组,研究组41例接受卡瑞利珠单抗联合术前新辅助化疗治疗,对照组41例接受术前新辅助化疗,3周为1个疗程,2组均治疗2个疗程。比较2组治疗效果,治疗前、治疗2个疗程后T淋巴细胞亚群、肿瘤标志物水平,治疗期间不良反应发生情况。结果 治疗2个疗程后,相较于对照组,研究组总有效率更高(P<0.05)。较治疗前,治疗2个疗程后2组全血CD4^(+)/CD8^(+)、CD4^(+)水平降低,但研究组更高(P<0.05)。2组患者血清里的角质蛋白21-1(CYERA21-1)、神经元特异性烯醇化酶(NSE)及癌胚抗原(CEA)水平相较于治疗前,治疗2个疗程后全部出现了下降情况,且研究组低于对照组(P<0.05)。治疗期间2组患者不良反应发生率对比,差异无统计学意义(P>0.05)。结论 化疗结合卡瑞利珠单抗在Ⅲ期NSCLC患者术前新辅助治疗中的应用效果较好,可调节T淋巴细胞亚群,降低肿瘤标志物水平,且不增加治疗安全风险。Objective To analyze the application effect of carrelizumab combined with chemotherapy in preoperative neoadjuvant therapy for patients with stageⅢnon-small cell lung cancer(NSCLC).Methods A total of 82 patients with NSCLC(stageⅢ)were selected and randomly divided into 2 groups.The study group(41 cases)received carrelizumab combined with preoperative neoadjuvant chemotherapy,and the control group(41 cases)received preoperative neoadjuvant chemotherapy.Three weeks was a course of treatment.Both groups were treated for 2 courses.The imaging evaluation after 2 courses of treatment,T lymphocyte subsets,tumor markers before and after 2 courses of treatment,and the incidence of adverse reactions during treatment were compared between the 2 groups.Results After 2 courses of treatment,the total effective rate in the study group was higher than the control group(P<0.05).Compared with before treatment,the levels of CD4^(+)/CD8^(+)and CD4^(+)in whole blood of the 2 groups decreased after 2 courses of treatment,but higher in the study group(P<0.05).Compared with before treatment,serum levels of neuronal specific enolase(NSE),keratinin-21-1(CYERA21-1)and carcinoembryonic antigen(CEA)were lower in the 2 groups after 2 courses of treatment,and lower in the study group(P<0.05).During treatment,there was no significant difference in the incidence of adverse reactions between the 2 groups(P>0.05).Conclusion Carrellizumab combined with chemotherapy has good effect on preoperative neoadjuvant therapy in patients with stageⅢNSCLC,which can regulate T lymphocyte subsets and reduce the level of tumor markers without increasing the risk of treatment safety.

关 键 词：卡瑞利珠单抗 化疗 非小细胞肺癌 Ⅲ期 新辅助治疗 T淋巴细胞亚群 肿瘤标志物 

分 类 号：R734.2[医药卫生—肿瘤]